Search research articles
Contact Us
Filters
Showing results (151-160 of 176) with videos related to
Page
of 18
Sort By:
The Lancet. Oncology
|
April 20, 2013
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P Mossé, Megan S Lim, Stephan D Voss, et al.
Pediatric Blood & Cancer
|
December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)
Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
Elizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group
Suman Malempati, Brenda Weigel, Ashish M Ingle, et al.
Pediatric Blood & Cancer
|
May 7, 2015
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group
Kelly D Getz, Yimei Li, Todd A Alonzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2014
AACR Cancer Progress Report 2014
Carlos L Arteaga, Peter C Adamson, Jeffrey A Engelman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2014
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment
Jeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2016
Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment
Jeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
Kaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Antimicrobial Agents and Chemotherapy
|
October 28, 2005
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents
Thomas J Walsh, Peter C Adamson, Nita L Seibel, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 176) with videos related to
Sort By:
Page
of 18
The Lancet. Oncology
|
April 20, 2013
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P Mossé, Megan S Lim, Stephan D Voss, et al.
Pediatric Blood & Cancer
|
December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)
Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
Elizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group
Suman Malempati, Brenda Weigel, Ashish M Ingle, et al.
Pediatric Blood & Cancer
|
May 7, 2015
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group
Kelly D Getz, Yimei Li, Todd A Alonzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2014
AACR Cancer Progress Report 2014
Carlos L Arteaga, Peter C Adamson, Jeffrey A Engelman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2014
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment
Jeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2016
Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment
Jeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
Kaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Antimicrobial Agents and Chemotherapy
|
October 28, 2005
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents
Thomas J Walsh, Peter C Adamson, Nita L Seibel, et al.
Page
of 18